Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
ann.graul@thomsonreuters.com
In the face of patent expirations on blockbuster drugs and declining innovation in the industry, pharma/biotech companies are restructuring their research and development operations and are pursuing an aggressive strategy of acquisitions, licensing deals and research collaborations in an attempt to fill the gaps in their product pipelines.
Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on